Date published: 2026-1-11

1-800-457-3801

SCBT Portrait Logo
Seach Input

GIDRP88 Inhibitors

GIDRP88 inhibitors constitute a unique class of chemical compounds designed to selectively impede the activity of the GIDRP88 protein. They function by targeting the molecular machinery that regulates the protein's activity, stability, or interactions with other cellular components. These inhibitors are designed based on the understanding of GIDRP88's role within specific cellular pathways, particularly those involved in signal transduction, protein folding, and degradation processes. By binding to the active or allosteric sites of GIDRP88, these molecules can modify the protein's conformation, leading to a reduction in its functional activity. This conformational change can prevent GIDRP88 from interacting with its substrates or from being properly integrated into larger protein complexes, which is crucial for its functional role within the cell. The precision of these inhibitors is a result of extensive research into the structure and function of GIDRP88, enabling the development of compounds that are highly specific to the intended target and that work to disrupt the protein's activity through various biochemical mechanisms.

The efficacy of GIDRP88 inhibitors is linked to their ability to interfere with the protein's regulatory mechanisms. When GIDRP88's regulatory function is compromised, there is a subsequent impact on the downstream pathways that rely on its activity. This cascade effect can lead to the dampening of specific signaling events, which are critical for certain cellular responses. The inhibitors can alter the protein's activity by preventing post-translational modifications that are necessary for its full activation or by blocking the association with co-factors that are required for its function. These targeted actions make GIDRP88 inhibitors a focal point of research, as they offer insights into the fundamental aspects of cellular regulation. By elucidating the precise interactions and effects of these inhibitors on GIDRP88, scientists gain a deeper understanding of the protein's role in the intricate network of cellular processes, while also paving the way for advancements in biochemical research that hinges on the modulation of specific protein functions.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin binds to FKBP12 and the complex inhibits mTOR, which is essential for the PI3K/AKT pathway. Since the PI3K/AKT pathway is implicated in regulating GIDRP88, inhibition of this pathway by rapamycin would result in decreased activity of GIDRP88.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin is an irreversible inhibitor of PI3K. Inhibition of PI3K prevents the activation of AKT, leading to the inactivation of downstream targets including GIDRP88.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 is a chemical inhibitor of PI3K, and by blocking PI3K, it subsequently prevents AKT activation and the subsequent downstream signaling that would normally enhance the activity of GIDRP88.

Triciribine

35943-35-2sc-200661
sc-200661A
1 mg
5 mg
$104.00
$141.00
14
(1)

Triciribine specifically inhibits the phosphorylation and activation of AKT, which is involved in signaling pathways that would otherwise lead to increased activity of GIDRP88.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

Erlotinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is upstream of the PI3K/AKT pathway. Inhibition of this pathway will reduce signaling through GIDRP88.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Gefitinib is an EGFR inhibitor which would decrease signaling through the PI3K/AKT pathway, thereby reducing the functional activity of GIDRP88.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Lapatinib is a dual tyrosine kinase inhibitor that targets both HER2 and EGFR, leading to downregulation of the PI3K/AKT pathway and subsequent reduction in GIDRP88 activity.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Sorafenib is a RAF inhibitor which also indirectly inhibits the PI3K/AKT pathway. By doing so, it can decrease the functional activity of GIDRP88.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Sunitinib inhibits multiple receptor tyrosine kinases, including PDGFR and VEGFR, which are involved in the PI3K/AKT signaling pathway, thus potentially decreasing the activity of GIDRP88.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Dasatinib is a Src family kinase inhibitor that also impacts the PI3K/AKT pathway. Inhibition of this pathway leads to a reduction in GIDRP88 activity.